Partner David Rosen was featured in a Clinical Leader Q&A, “Clinical Trial Deaths — Will Clearer Informed Consent Documents Be Enough?” about issues related to clinical trial consent documents, particularly as they relate to the lawsuit filed against the FDA by the Center for Responsible Science, clinical trial participants and the father of a deceased trial participant.
Rosen answered questions about whether or not the lawsuit will be successful, whether or not the current death rate from clinical trial treatments is concerning and what steps clinical trial stakeholders need to take to improve the informed consent process and make trials safer for patients.
Rosen answered questions about whether or not the lawsuit will be successful, whether or not the current death rate from clinical trial treatments is concerning and what steps clinical trial stakeholders need to take to improve the informed consent process and make trials safer for patients.
People
Related News
04 October 2024
In the News
Rajiv Dharnidharka and Jeanette Barzelay Featured Across Legal Press for Move to Foley
Recent laterals Rajiv Dharnidharka and Jeanette Barzelay are featured across legal press for their arrival to Foley, including in the Law360 article, "Foley Adds 2 DLA Piper Business Litigators In San Francisco."
04 October 2024
In the News
Chanley Howell on AI IP Protection in Litigation – 'Judges are human'
Foley & Lardner LLP partner Chanley Howell shared insight on protecting the intellectual property behind emerging technologies like artificial intelligence in the Bloomberg Law article, "AI Put on Trial in ‘Life or Death’ Police Tech Clashes."
01 October 2024
In the News
Natasha Allen on DEI Challenges for Corporate Boards – 'Diversity is necessary for companies to succeed'
Foley & Lardner LLP partner Natasha Allen authored the article, "Navigating Today's DEI Challenges," in the November/December issue of Corporate Governance Advisor.